drugset / Trial / NCT06415045

A Study in Healthy People to Test How BI 1015550 is Taken up in the Body When Given With or Without Food

NCT06415045

Phase 1 Completed 18 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

The main objective is to investigate the effect of food on the pharmacokinetics of BI 1015550 Formulation C2.

Timeline

Start
2024-05-28
Primary completion
2024-07-24
Completion
2024-07-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Nerandomilast Small molecule 18 mg Oral

Indications

No indication recorded.